Literature DB >> 21629130

Variable cardiac 18FDG patterns seen in oncologic positron emission tomography computed tomography: importance for differentiating normal physiology from cardiac and paracardiac disease.

Alan H Maurer1, Mark Burshteyn, Lee P Adler, John P Gaughan, Robert M Steiner.   

Abstract

PURPOSE: Cardiac fluorine-18-fluorodeoxyglucose (FDG) uptake is known to be variable in fasting oncologic positron emission tomography computed tomography studies. Increased posterolateral and basal FDG activity have been reported with the basal pattern ascribed to radiation injury. The purpose of this study was to investigate the spectrum of normal cardiac FDG findings seen in oncologic patients.
MATERIALS AND METHODS: Men <35 years of age and women <45 years of age seen over a 3-year period were included. A visual assessment of FDG cardiac activity was performed using a 12-segment model of the heart by 2 observers. Focal papillary muscle activity was not included in the analysis.
RESULTS: Of 65 patients who met the entry criteria, increased FDG activity was observed in the base of the heart in 37 (57%) patients. This was most common in the lateral-basal wall in 35 (54%) patients, followed by posterior-basal wall in 21 (32%) patients, anterior-basal wall in 10 (15%) patients, and basal-septum in 10 (15%) patients. Suppression of total cardiac activity was present in only 6 (9%) patients in spite of adequate fasting. Diffuse cardiac activity was seen in 9 (14%) patients. The previously reported increased posterolateral pattern was present in only 9 (14%) patients.
CONCLUSION: This study confirms variable fasting FDG cardiac activity with a predominant basal pattern not associated with radiation injury. Knowledge of these patterns is important for recognition of possible underlying cardiac ischemia, tumor, or other inflammatory conditions encountered during interpretation of oncologic positron emission tomography computed tomography studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21629130     DOI: 10.1097/RTI.0b013e3182176675

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  7 in total

1.  Optimizing radionuclide imaging in the assessment of cardiac sarcoidosis.

Authors:  John P Bois; Panithaya Chareonthaitawee
Journal:  J Nucl Cardiol       Date:  2015-08-13       Impact factor: 5.952

2.  Effect of prolonged fasting and low molecular weight heparin or warfarin therapies on 2-deoxy-2-[18F]-fluoro-D-glucose PET cardiac uptake.

Authors:  Assuero Giorgetti; Gavino Marras; Dario Genovesi; Elena Filidei; Antonio Bottoni; Maurizio Mangione; Michele Emdin; Paolo Marzullo
Journal:  J Nucl Cardiol       Date:  2017-02-03       Impact factor: 5.952

3.  F-18 sodium fluoride PET/CT does not effectively image myocardial inflammation due to suspected cardiac sarcoidosis.

Authors:  Richard L Weinberg; Rachelle Morgenstern; Albert DeLuca; Jennifer Chen; Sabahat Bokhari
Journal:  J Nucl Cardiol       Date:  2016-05-19       Impact factor: 5.952

Review 4.  Series of myocardial FDG uptake requiring considerations of myocardial abnormalities in FDG-PET/CT.

Authors:  Ryogo Minamimoto
Journal:  Jpn J Radiol       Date:  2021-01-31       Impact factor: 2.374

5.  Characterization and compensation of f 0 inhomogeneity artifact in spiral hyperpolarized 13 C imaging of the human heart.

Authors:  Galen D Reed; Junjie Ma; Jae Mo Park; Rolf F Schulte; Crystal E Harrison; Albert P Chen; Salvador Pena; Jeannie Baxter; Kelly Derner; Maida Tai; Jaffar Raza; Jeff Liticker; Ronald G Hall; A Dean Sherry; Vlad G Zaha; Craig R Malloy
Journal:  Magn Reson Med       Date:  2021-02-05       Impact factor: 3.737

Review 6.  Assessment of cardiac sarcoidosis with advanced imaging modalities.

Authors:  Makoto Orii; Toshio Imanishi; Takashi Akasaka
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

7.  A dual tracer (68)Ga-DOTANOC PET/CT and (18)F-FDG PET/CT pilot study for detection of cardiac sarcoidosis.

Authors:  Lars C Gormsen; Ate Haraldsen; Stine Kramer; Andre H Dias; Won Yong Kim; Per Borghammer
Journal:  EJNMMI Res       Date:  2016-06-17       Impact factor: 3.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.